+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients NSABP studies B-20 and B-14



Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients NSABP studies B-20 and B-14



Breast Cancer Research & Treatment 82(Supplement 1): S10-S11




(PDF emailed within 1 workday: $29.90)

Accession: 035349232

Download citation: RISBibTeXText


Related references

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. Journal of Clinical Oncology 28(10): 1677-1683, 2010

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Research and Treatment 127(1): 133-142, 2011

Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients M D Anderson Clinical Validation Study. Breast Cancer Research & Treatment 82(Supplement 1): S11, 2003

Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. Journal of Clinical Oncology 23(16_suppl): 510-510, 2016

A Multigene Assay for Predicting the Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. Breast Diseases: A Year Book Quarterly 16(3): 219-220, 2005

Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Research and Treatment 133(3): 1115-1123, 2012

Predicting recurrence in axillary-node negative breast cancer patients. Breast Cancer Research & Treatment 25(2): 127-139, 1993

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. Journal of Clinical Oncology 28(11): 1829-1834, 2010

Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. Journal of Clinical Oncology 14(7): 1982-1992, 1996

Predicting recurrence in axillary node negative breast cancer patients using adaptive artificial intelligence. Breast Cancer Research & Treatment 16(2): 190, 1990

Predicting recurrence in axillary node negative breast cancer patients 10 year follow up results. Proceedings of the American Association for Cancer Research Annual Meeting 33: 212, 1992

Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?. Expert Review of Pharmacoeconomics & Outcomes Research 13(2): 243-250, 2013

The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous?. European Journal of Cancer 68: 173-175, 2016

Prognostic factors in NSABP studies of women with node-negative breast cancer. Journal of the National Cancer Institute Monographs 0(11): 151-158, 1992

Prognostic factors in NSABP studies of women with node-negative breast cancer. National Surgical Adjuvant Breast and Bowel Project. Journal of the National Cancer Institute. Monographs: 151-158, 1992